These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15582280)

  • 1. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis.
    Dedeoglu A; Cormier K; Payton S; Tseitlin KA; Kremsky JN; Lai L; Li X; Moir RD; Tanzi RE; Bush AI; Kowall NW; Rogers JT; Huang X
    Exp Gerontol; 2004; 39(11-12):1641-9. PubMed ID: 15582280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease.
    Rodríguez-Rodríguez C; Sánchez de Groot N; Rimola A; Alvarez-Larena A; Lloveras V; Vidal-Gancedo J; Ventura S; Vendrell J; Sodupe M; González-Duarte P
    J Am Chem Soc; 2009 Feb; 131(4):1436-51. PubMed ID: 19133767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice.
    Lee JY; Friedman JE; Angel I; Kozak A; Koh JY
    Neurobiol Aging; 2004; 25(10):1315-21. PubMed ID: 15465629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease.
    Reznichenko L; Amit T; Zheng H; Avramovich-Tirosh Y; Youdim MB; Weinreb O; Mandel S
    J Neurochem; 2006 Apr; 97(2):527-36. PubMed ID: 16539659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
    Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF
    J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
    van Groen T; Kiliaan AJ; Kadish I
    Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease.
    Liu K; Solano I; Mann D; Lemere C; Mercken M; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2006 Aug; 112(2):163-74. PubMed ID: 16865398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta.
    Adlard PA; Cherny RA; Finkelstein DI; Gautier E; Robb E; Cortes M; Volitakis I; Liu X; Smith JP; Perez K; Laughton K; Li QX; Charman SA; Nicolazzo JA; Wilkins S; Deleva K; Lynch T; Kok G; Ritchie CW; Tanzi RE; Cappai R; Masters CL; Barnham KJ; Bush AI
    Neuron; 2008 Jul; 59(1):43-55. PubMed ID: 18614028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis.
    Carro E; Trejo JL; Gerber A; Loetscher H; Torrado J; Metzger F; Torres-Aleman I
    Neurobiol Aging; 2006 Sep; 27(9):1250-7. PubMed ID: 16183170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents.
    Mandel S; Amit T; Bar-Am O; Youdim MB
    Prog Neurobiol; 2007 Aug; 82(6):348-60. PubMed ID: 17659826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metal exposure and Alzheimer's pathogenesis.
    Liu G; Huang W; Moir RD; Vanderburg CR; Lai B; Peng Z; Tanzi RE; Rogers JT; Huang X
    J Struct Biol; 2006 Jul; 155(1):45-51. PubMed ID: 16503166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid beta peptide levels.
    Pacheco-Quinto J; Rodriguez de Turco EB; DeRosa S; Howard A; Cruz-Sanchez F; Sambamurti K; Refolo L; Petanceska S; Pappolla MA
    Neurobiol Dis; 2006 Jun; 22(3):651-6. PubMed ID: 16516482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia increases Abeta generation by altering beta- and gamma-cleavage of APP.
    Li L; Zhang X; Yang D; Luo G; Chen S; Le W
    Neurobiol Aging; 2009 Jul; 30(7):1091-8. PubMed ID: 18063223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraneuronal amyloid beta and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease.
    Van Broeck B; Vanhoutte G; Pirici D; Van Dam D; Wils H; Cuijt I; Vennekens K; Zabielski M; Michalik A; Theuns J; De Deyn PP; Van der Linden A; Van Broeckhoven C; Kumar-Singh S
    Neurobiol Aging; 2008 Feb; 29(2):241-52. PubMed ID: 17112635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: implications for Alzheimer beta-amyloid pathology.
    Maynard CJ; Cappai R; Volitakis I; Cherny RA; Masters CL; Li QX; Bush AI
    J Inorg Biochem; 2006 May; 100(5-6):952-62. PubMed ID: 16574231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease.
    Lafay-Chebassier C; Paccalin M; Page G; Barc-Pain S; Perault-Pochat MC; Gil R; Pradier L; Hugon J
    J Neurochem; 2005 Jul; 94(1):215-25. PubMed ID: 15953364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.
    Guix FX; Ill-Raga G; Bravo R; Nakaya T; de Fabritiis G; Coma M; Miscione GP; Villà-Freixa J; Suzuki T; Fernàndez-Busquets X; Valverde MA; de Strooper B; Muñoz FJ
    Brain; 2009 May; 132(Pt 5):1335-45. PubMed ID: 19251756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host.
    Meyer-Luehmann M; Coomaraswamy J; Bolmont T; Kaeser S; Schaefer C; Kilger E; Neuenschwander A; Abramowski D; Frey P; Jaton AL; Vigouret JM; Paganetti P; Walsh DM; Mathews PM; Ghiso J; Staufenbiel M; Walker LC; Jucker M
    Science; 2006 Sep; 313(5794):1781-4. PubMed ID: 16990547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease.
    Opazo C; Luza S; Villemagne VL; Volitakis I; Rowe C; Barnham KJ; Strozyk D; Masters CL; Cherny RA; Bush AI
    Aging Cell; 2006 Feb; 5(1):69-79. PubMed ID: 16441845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.